362 related articles for article (PubMed ID: 22213157)
61. Managing diabetic dyslipidemia: beyond statin therapy.
Neeli H; Gadi R; Rader DJ
Curr Diab Rep; 2009 Feb; 9(1):11-7. PubMed ID: 19192419
[TBL] [Abstract][Full Text] [Related]
62. Fenofibrate: a review of its use in dyslipidaemia.
McKeage K; Keating GM
Drugs; 2011 Oct; 71(14):1917-46. PubMed ID: 21942979
[TBL] [Abstract][Full Text] [Related]
63. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
64. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus.
Elam M; Lovato L; Ginsberg H
Clin Lipidol; 2011; 6(1):9-20. PubMed ID: 26207146
[TBL] [Abstract][Full Text] [Related]
65. Use of fibrates in the United States and Canada.
Jackevicius CA; Tu JV; Ross JS; Ko DT; Carreon D; Krumholz HM
JAMA; 2011 Mar; 305(12):1217-24. PubMed ID: 21427374
[TBL] [Abstract][Full Text] [Related]
66. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
67. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
68. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
69. Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.
Vavlukis M; Kedev S
Curr Pharm Des; 2018; 24(4):427-441. PubMed ID: 29283060
[TBL] [Abstract][Full Text] [Related]
70. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Linz PE; Lovato LC; Byington RP; O'Connor PJ; Leiter LA; Weiss D; Force RW; Crouse JR; Ismail-Beigi F; Simmons DL; Papademetriou V; Ginsberg HN; Elam MB
Diabetes Care; 2014; 37(3):686-93. PubMed ID: 24296848
[TBL] [Abstract][Full Text] [Related]
71. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
González Santos P
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
[TBL] [Abstract][Full Text] [Related]
72. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
73. Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials.
Sahebkar A; Watts GF
Atherosclerosis; 2013 Sep; 230(1):110-20. PubMed ID: 23958262
[TBL] [Abstract][Full Text] [Related]
74. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
Farnier M
Vasc Health Risk Manag; 2008; 4(5):991-1000. PubMed ID: 19183747
[TBL] [Abstract][Full Text] [Related]
75. Benefits and risks of the treatment with fibrates--a comprehensive summary.
Okopień B; Bułdak Ł; Bołdys A
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
[TBL] [Abstract][Full Text] [Related]
76. Effects of combination lipid therapy in type 2 diabetes mellitus.
; Ginsberg HN; Elam MB; Lovato LC; Crouse JR; Leiter LA; Linz P; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm RH; Ismail-Beigi F; Bigger JT; Goff DC; Cushman WC; Simons-Morton DG; Byington RP
N Engl J Med; 2010 Apr; 362(17):1563-74. PubMed ID: 20228404
[TBL] [Abstract][Full Text] [Related]
77. Significant increase in high-density lipoprotein cholesterol with fibrates is associated with low pretreatment high-density lipoprotein cholesterol: findings from an outpatient clinic setting.
Ramachandran S; Abbas A; Saraf S; Raju J; Jewkes C; Jones AF
Metab Syndr Relat Disord; 2012 Jun; 10(3):189-94. PubMed ID: 22283634
[TBL] [Abstract][Full Text] [Related]
78. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
[TBL] [Abstract][Full Text] [Related]
79. Association between triglyceride and high-density lipoprotein cholesterol change following fibrate therapy.
Collins MW; König CS; Abbas A; Jewkes C; Jones AF; Ramachandran S
Diabetes Metab Syndr; 2014; 8(4):212-5. PubMed ID: 25301006
[TBL] [Abstract][Full Text] [Related]
80. Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.
Standl E
Diab Vasc Dis Res; 2013 Mar; 10(2):99-114. PubMed ID: 22718811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
